Literature DB >> 31786200

NMDA receptors containing GluN2C and GluN2D subunits have opposing roles in modulating neuronal oscillations; potential mechanism for bidirectional feedback.

Zhihao Mao1, Shengxi He1, Christopher Mesnard1, Paul Synowicki1, Yuning Zhang1, Lucy Chung1, Alex I Wiesman2, Tony W Wilson2, Daniel T Monaghan3.   

Abstract

NMDA receptor (NMDAR) antagonists such as ketamine, can reproduce many of the symptoms of schizophrenia. A reliable indicator of NMDAR channel blocker action in vivo is the augmentation of neuronal oscillation power. Since the coordinated and rhythmic activation of neuronal assemblies (oscillations) is necessary for perception, cognition and working memory, their disruption (inappropriate augmentation or inhibition of oscillatory power or inter-regional coherence) both in psychiatric conditions and with NMDAR antagonists may reflect the underlying defects causing schizophrenia symptoms. NMDAR antagonists and knockout (KO) mice were used to evaluate the role of GluN2C and GluN2D NMDAR subunits in generating NMDAR antagonist-induced oscillations. We find that basal oscillatory power was elevated in GluN2C-KO mice, especially in the low gamma frequencies while there was no statistically significant difference in basal oscillations between WT and GluN2D-KO mice. Compared to wildtype (WT) mice, NMDAR channel blockers caused a greater increase in oscillatory power in GluN2C-KO mice and were relatively ineffective in inducing oscillations in GluN2D-KO mice. In contrast, preferential blockade of GluN2A- and GluN2B-containing receptors induced oscillations that did not appear to be changed in either KO animal. We propose a model wherein NMDARs containing GluN2C in astrocytes and GluN2D in interneurons serve to detect local cortical excitatory synaptic activity and provide excitatory and inhibitory feedback, respectively, to local populations of postsynaptic excitatory neurons and thereby bidirectionally modulate oscillatory power.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Astrocyte; Electrocorticography; Interneuron; Ketamine; NMDA receptors; Schizophrenia

Year:  2019        PMID: 31786200      PMCID: PMC7193694          DOI: 10.1016/j.brainres.2019.146571

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  100 in total

1.  Cloning and expression of the epsilon 4 subunit of the NMDA receptor channel.

Authors:  K Ikeda; M Nagasawa; H Mori; K Araki; K Sakimura; M Watanabe; Y Inoue; M Mishina
Journal:  FEBS Lett       Date:  1992-11-16       Impact factor: 4.124

2.  Developmental changes in distribution of NMDA receptor channel subunit mRNAs.

Authors:  M Watanabe; Y Inoue; K Sakimura; M Mishina
Journal:  Neuroreport       Date:  1992-12       Impact factor: 1.837

3.  SNARE protein-dependent glutamate release from astrocytes.

Authors:  A Araque; N Li; R T Doyle; P G Haydon
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

4.  Thalamic-prefrontal cortical-ventral striatal circuitry mediates dissociable components of strategy set shifting.

Authors:  Annie E Block; Hasina Dhanji; Sarah F Thompson-Tardif; Stan B Floresco
Journal:  Cereb Cortex       Date:  2006-09-08       Impact factor: 5.357

5.  NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

6.  Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor.

Authors:  J D Clements; G L Westbrook
Journal:  Neuron       Date:  1991-10       Impact factor: 17.173

7.  Hippocampal Protein Kinase C Signaling Mediates the Short-Term Memory Impairment Induced by Delta9-Tetrahydrocannabinol.

Authors:  Arnau Busquets-Garcia; Maria Gomis-González; Victòria Salgado-Mendialdúa; Lorena Galera-López; Emma Puighermanal; Elena Martín-García; Rafael Maldonado; Andrés Ozaita
Journal:  Neuropsychopharmacology       Date:  2017-08-17       Impact factor: 7.853

8.  Astrocytes contribute to gamma oscillations and recognition memory.

Authors:  Hosuk Sean Lee; Andrea Ghetti; António Pinto-Duarte; Xin Wang; Gustavo Dziewczapolski; Francesco Galimi; Salvador Huitron-Resendiz; Juan C Piña-Crespo; Amanda J Roberts; Inder M Verma; Terrence J Sejnowski; Stephen F Heinemann
Journal:  Proc Natl Acad Sci U S A       Date:  2014-07-28       Impact factor: 11.205

9.  Cytosolic calcium oscillations in astrocytes may regulate exocytotic release of glutamate.

Authors:  L Pasti; M Zonta; T Pozzan; S Vicini; G Carmignoto
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

10.  Subunit-specific NMDAR antagonism dissociates schizophrenia subtype-relevant oscillopathies associated with frontal hypofunction and hippocampal hyperfunction.

Authors:  Benjamin Pittman-Polletta; Kun Hu; Bernat Kocsis
Journal:  Sci Rep       Date:  2018-08-02       Impact factor: 4.379

View more
  3 in total

1.  Astrocyte GluN2C NMDA receptors control basal synaptic strengths of hippocampal CA1 pyramidal neurons in the stratum radiatum.

Authors:  Chi Chung Alan Fung; Alejandra Pazo Fernandez; Peter H Chipman; Abhilash Sawant; Angelo Tedoldi; Atsushi Kawai; Sunita Ghimire Gautam; Mizuki Kurosawa; Manabu Abe; Kenji Sakimura; Tomoki Fukai; Yukiko Goda
Journal:  Elife       Date:  2021-10-25       Impact factor: 8.140

2.  Facilitation of GluN2C-containing NMDA receptors in the external globus pallidus increases firing of fast spiking neurons and improves motor function in a hemiparkinsonian mouse model.

Authors:  Jinxu Liu; Gajanan P Shelkar; Lopmudra P Sarode; Dinesh Y Gawande; Fabao Zhao; Rasmus Praetorius Clausen; Rajesh R Ugale; Shashank Manohar Dravid
Journal:  Neurobiol Dis       Date:  2021-01-06       Impact factor: 5.996

3.  Multiple roles of GluN2D-containing NMDA receptors in short-term potentiation and long-term potentiation in mouse hippocampal slices.

Authors:  Alen V Eapen; Diego Fernández-Fernández; John Georgiou; Zuner A Bortolotto; Stafford Lightman; David E Jane; Arturas Volianskis; Graham L Collingridge
Journal:  Neuropharmacology       Date:  2021-10-09       Impact factor: 5.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.